• Cellvizio®
    • Overview
    • Education
    • Economics
    • Indications
      • Gastroenterology
        • Barrett’s Esophagus
        • Pancreatic Cysts
        • Gastric Disease
        • Inflammatory Bowel Diseases
        • Irritable Bowel Syndrome – Food Intolerance
        • Bilio-Pancreatic Strictures
        • Colorectal Lesions
      • Pulmonology
        • Lung Nodules
        • Lung Transplant
      • Urology
  • Investors
    • Overview
    • Events and Presentations
    • Financials
    • Governance
  • About Us
    • Our Story
    • Team
      • Board of Directors
      • Leadership Team
    • Join Us
    • Commercial Network
  • Newsroom
    • News
    • Events
    • Press Coverage
  • US
    • INT
    • FR
Mauna Kea Technologies Announces a New Publication in Nature Scientific Reports Demonstrating the Accuracy of Cellvizio® for Food Allergy Diagnosis

Mauna Kea Technologies Announces a New Publication in Nature Scientific Reports Demonstrating the Accuracy of Cellvizio® for Food Allergy Diagnosis

by Zina | Jun 22, 2021 | News

New peer-reviewed evidence that Cellvizio can be used as a screening tool in patients with suspected food allergy  Mauna Kea Technologies today announces a peer-reviewed publication in the journal Nature Scientific Reports entitled “Cross-sectional...
Mauna Kea Technologies Unveils Its Next-Generation Cellvizio® Platform

Mauna Kea Technologies Unveils Its Next-Generation Cellvizio® Platform

by Zina | Jun 14, 2021 | News

Launch of the new system is part of the company’s mission to deliver an enhanced platform combining advanced imaging, digital health informatics, and improved patient outcomes  Mauna Kea Technologies today unveiled the next-generation Cellvizio...
Mauna Kea Technologies Unveils Its Next-Generation Cellvizio® Platform

Mauna Kea Technologies Announces 7 Presentations Highlighting the Clinical Value of Cellvizio® in Gastrointestinal Diseases at Digestive Disease Week® (DDW) 2021 Virtual™

by Zina | May 20, 2021 | News

Further validation of how the use of Cellvizio potentially impacts patient management and improves outcomes in multiple gastrointestinal indications  Mauna Kea Technologies today announced the presentation of 7 abstracts supporting Cellvizio® at...
Mauna Kea Technologies Announces a New Publication in Nature Scientific Reports Demonstrating the Accuracy of Cellvizio® for Food Allergy Diagnosis

Mauna Kea Technologies Announces it has Signed its 15th Hospital in Europe for Irritable Bowel Syndrome (IBS) Food Allergy Application

by Zina | May 5, 2021 | News

Confirming the Role and added value of Cellvizio for the Identification and Management of IBS Patients with Atypical Food Allergies  Mauna Kea Technologies continues to expand its European customer base in healthcare centers treating patients with Irritable...
Mauna Kea Technologies reports second half and full year 2020 financial results and first quarter of 2021 sales

Mauna Kea Technologies reports second half and full year 2020 financial results and first quarter of 2021 sales

by Zina | Apr 22, 2021 | News

Strong 2H’20 financial results driven by 27% sales growth and a 15% reduction in net loss compared to prior year period  The Company expects to deliver 25% to 30% sales growth for full year 2021 period  Mauna Kea Technologies today announced...
« Older Entries
Next Entries »

Articles récents

  • Mauna Kea Technologies Announces Largest Annual Pancreatic Cyst Consortium at Digestive Disease Week® 2025 
  • Publication of the 2024 Annual Financial Report 
  • Digestive Disease Week 2025
  • Mauna Kea Technologies Announces Another Milestone Year at Digestive Disease Week® 2025 with 8 Presentations Demonstrating the Clinical Value of Cellvizio® in Key Indications 
  • Mauna Kea Technologies Reports Full Year 2024 Results and Provides a Business Update 

Commentaires récents

No comments to show.

Company Info

About Us

Join Us

Contact Us

Legal

Legal notice

Privacy policy

Our websites

Cellvizio.net

cell-tolerance.com

Diagnosingbarretts.org

Diagnosingpancreaticcysts.org

Follow us

  • Follow
  • Follow
  • Follow
  • Follow
Manage Consent
To provide the best experiences, we use technologies like cookies to store and/or access device information. Consenting to these technologies will allow us to process data such as browsing behavior or unique IDs on this site. Not consenting or withdrawing consent, may adversely affect certain features and functions.
Functional Always active
The technical storage or access is strictly necessary for the legitimate purpose of enabling the use of a specific service explicitly requested by the subscriber or user, or for the sole purpose of carrying out the transmission of a communication over an electronic communications network.
Preferences
The technical storage or access is necessary for the legitimate purpose of storing preferences that are not requested by the subscriber or user.
Statistics
The technical storage or access that is used exclusively for statistical purposes. The technical storage or access that is used exclusively for anonymous statistical purposes. Without a subpoena, voluntary compliance on the part of your Internet Service Provider, or additional records from a third party, information stored or retrieved for this purpose alone cannot usually be used to identify you.
Marketing
The technical storage or access is required to create user profiles to send advertising, or to track the user on a website or across several websites for similar marketing purposes.
Manage options Manage services Manage {vendor_count} vendors Read more about these purposes
View preferences
{title} {title} {title}